A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

• Status: Terminated
• Trial end date: 2005-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of ziprasidone in acute exacerbation of schizophrenia or schizoaffective disorder, including patients with recent onset of symptoms

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Ziprasidone

Criteria

Inclusion Criteria:

• Patients not currently being treated with antipsychotic medication and neuroleptic naive patients

• Diagnosis of schizophrenia or schizoaffective disorder

• Antipsychotic treatment prior to screening was to be for a cumulative period of less than 5 years

Exclusion Criteria:

• Patients at immediate risk of committing harm to self or others

• Treatment with clozapine within 3 months prior to baseline

• History of neuroleptic treatment

• Current antipsychotic treatment